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Objective. To determine the concentration of selected haemostatic factors (HFs): thrombin–antithrombin complexes (TAT),
antithrombin (AT), tissue plasminogen activator (t-PA), plasminogen activator inhibitor type 1 (PAI-1) and D-dimers in
carotid bifurcation plaques and to compare plaque composition in different subgroups of patients (mainly those with
symptomatic and asymptomatic carotid stenosis).
Materials and methods. Thirty-eight consecutive patients (20 symptomatic, 18 asymptomatic) undergoing carotid
endarterectomy were enrolled in the study. The concentration of selected HFs in carotid plaques was measured using mainly
enzyme immunoassay (ELISA). Simultaneously, the concentration of HFs in plasma was also obtained.
Results. Symptomatic plaques contained significantly more TATcomplexes (p ¼ 0.03). AT was found only in nine out of 38
carotid plaques and was present mainly in symptomatic carotid plaques (n ¼ 8/9)(p , 0.006). No significant differences
were found between symptomatic and asymptomatic carotid plaques with respect to t-PA, PAI-1 and D-dimers
concentration. There was an increased concentration of TAT (p , 0.001), t-PA (p , 0.02) and D-dimers (p , 0.02) in
carotid plaques of diabetic patients. Patients with coexisting intermittent claudication had elevated levels of D-dimers
in carotid plaques (p , 0.02). The only positive correlation was demonstrated between the concentration of AT in plasma
and carotid plaques (R ¼ 0.76; p ¼ 0.02).
Conclusions. All the evaluated HFs are the components of a carotid plaque. Symptomatic patients have increased
concentration of TAT complexes in a carotid plaque. The symptomatic carotid plaque contains AT more frequently, which
correlates positively with AT plasma levels. The most marked changes in the carotid plaque haemostatic composition
(expressed by elevated levels of TAT, t-PA and D-dimers) have diabetic patients.
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Introduction
The current problem is the destabilization of an
atherosclerotic plaque. It has been demonstrated that
inflammation plays a crucial role in the plaque
formation and destabilization process.4,5 Considering
the role of coagulation and fibrinolysis in an atheroma
formation one can suspect that these processes can
determine susceptibility of atherosclerotic plaque for
destabilization. Reports on atheroma progression and
destabilization process are based mainly on the
coronary artery biology and the role of haemostatic
factors (HFs) in stable and unstable atherosclerotic
plaque formation has been demonstrated mainly in
patients with acute coronary syndromes (ACS).17,25,26
Serial angiographic studies of coronary arteries in
patients with coronary artery disease demonstrated
that smooth progression of atheroma is rare.6,7
Three types of physical disruptions of atheroma
leading to plaque destabilization and acceleration of
growth of atherosclerotic lesions have been reported:
superficial erosion and desquamation of endothelial
cells; intra-plaque micro-haemorrhage due to plaque
neovascularization process and the most frequent: the
plaques fibrous cap fracture. The activation of coagu-
lation leading to thrombus formation is the effect of all
the three types of plaque disruption.8 – 10 HFs contrib-
ute to the unstable plaque formation playing a crucial
role in basic atherosclerotic plaque formation pro-
cesses (e.g. VSMCs proliferation and migration,
proteolysis, neointimalization, metalloproteinases
activation).
Thrombin stimulates vascular smooth muscle cells
(VSMCs) proliferation and migration and triggers
platelet release of growth factors (PDGF, TGF-b)
which further stimulate VSMCs proliferation and
migration and collagen synthesis leading to the
acceleration of atheroma growth. It has been demon-
strated that thrombin can influence not only the
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activity of endothelium and VSMCs, but also the
activity of macrophages, leukocytes and fibroblasts.11
The potent, multidirectional activity of thrombin can
induce the situation that a silent microvascular intra-
plaque haemorrhage could give rise to a growth
acceleration in the evolution of the plaque.8 – 10
Thrombin is not the only haemostatic factor playing
a crucial role in an atheroma formation. Through the
activation of proteolysis the tissue plasminogen
activator (t-PA) plays an important role in VSMCs
migration into the evolving atherosclerotic plaque,
noeintima formation and activation of matrix metallo-
proteinases (MMPs) that precipitate plaque rup-
ture.12 – 14 Proteofibrinolysis (including MMPs
activation) activated by t-PA can induce plaque
rupture and destabilization leading to embolization.
On the other hand prolonged elevated concentration
of t-PA during atherosclerotic plaque formation
facilitates stable plaque formation, which is resistant
to destabilization process. Increased expression of
plasminogen activator inhibitor type-1 (PAI-1) has
been demonstrated in atherosclerotic arteries.15,16 The
impact of PAI-1 on the atherogenesis remains con-
troversial. Different multidirectional activities of PAI-1
in atherogenesis seem contradictory. PAI-1 partici-
pates in the atherosclerotic plaque stabilization by
local inhibition of fibrinolysis. Increased expression of
PAI-1 in the arterial wall with atherosclerotic lesions
cause fibrin accumulation and increase the local risk of
thrombosis which induce acceleration of plaque
formation and arterial lumen occlusion.17 – 19 Elevated
level of PAI-1 during coronary plaque formation
process lead to inhibition of VSMCs proliferation and
migration which predisposes to acellular, lipid laden
unstable plaque formation. The protective role of PAI-
1 by limiting plaque growth and preventing abnormal
matrix remodelling has also been reported.20 PAI-1 in
collaboration with vitronectin plays crucial role in
neointima development.21 We can conclude that the
exact function of PAI-1 and t-PA in the atherosclerotic
lesions is not known.
We have not found reports widely describing the
concentration of haemostatic factors in human carotid
atherosclerotic plaque and their potential function in
carotid pathology. The role of local overexpression of
PAI-1 in rat carotid artery has been only reported.19
Considering the important role of coagulation and
fibrinolysis in atherosclerotic plaque formation one
can suspect that describing carotid plaque haemostatic
profile we could make another step in an attempt to
understand the mechanisms underlying carotid pla-
que activation.
The aim of our study was to identify the concen-
tration of selected haemostatic factors in carotid
atherosclerotic plaques of patients undergoing carotid
endarterectomy and to evaluate differences in concen-
tration of these factors in different subgroups of
patients especially those with symptomatic and
asymptomatic carotid stenosis. The purpose of the
study was also to evaluate the correlation between
levels of HFs in carotid plaque and blood plasma.
Material and Methods
Thirty-eight consecutive patients undergoing carotid
endarterectomy from February to November 2001 in
the Department of Surgery were recruited to the study.
At the time of preoperative period complete medical
history was taken, and the following risk factors and
coexisting diseases were recorded: sex, age, body
weight, hyperlipidemia (total cholesterol, LDL, HDL,
triglyceride), smoking status (1, never smoked; 2,
former smokers—quit .1 year; 3, current smoker),
peripheral arterial occlusive disease (ABPI ,0,9),
hypertension (under hypotensive therapy or blood
pressure $160/95 mmHg), coronary artery disease
(angina pectoris, myocardial infarction, coronary
artery bypass grafting procedure or PTCA) and
diabetes (patients on diet, oral hypoglycaemic agents,
insulin or with fasting glucose levels .126 mg/dl).
Patients were defined as symptomatic if symptoms
occurred less then 6 months before enrolment. The day
before the operation all patients had fat-free diet.
Samples preparation
Carotid plaques removed during endarterectomy
were washed carefully in saline and stored dry in the
temperature of 220 8C. The venous blood samples
(10 ml for haemostatic factors evaluation; 5 ml for
standard laboratory tests) were collected in fasting
state before the operation (8 a.m.). The blood was
sampled without venous stasis into the plastic
centrifugation-tube containing 3.8% natrium citrate
solution (1:10 proportion). Blood samples were cen-
trifuged immediately after sampling in order to obtain
platelet-free plasma (3000/min; 15 min). Platelet-free
plasma samples were stored in 220 8C. Five haemo-
static factors were tested in the study: thrombin–
antithrombin complexes (TAT), antithrombin (AT),
tissue plasminogen activator (t-PA), plasminogen
activator inhibitor type 1 (PAI-1) and D-dimers. After
preparation of carotid plaque homogenates the con-
centration of haemostatic factors was tested in the
laboratory of Department of Pathophysiology using
mainly enzyme immunoassay (ELISA). The antith-
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rombin concentration was measured using the test
based on chromogenic substrates. Tests used in the
study:
1. TAT: Enzygnost TAT micro—Dade Behring;
2. AT: Boehringer-Mannheim test;
3. t-PA: Imulyse t-PA—Biopool;
4. PAI-1: Imulyse PAI-1—Biopool;
5. D-dimers: TintElize D-dimers—Biopool.
The concentration of all tested haemostatic factors
in carotid plaques was calculated per milligram
protein of homogenates. The measurement of the
concentration of haemostatic factors in plasma
enabled the evaluation of correlation between levels
of tested factors in carotid plaques and blood plasma.
Statistical analysis
Normal distribution of data was determined by the
Shapiro – Wilk normality test. The relationship
between risk factors of arteriosclerosis, symptomatic
and asymptomatic carotid stenosis and the concen-
tration of haemostatic factors in carotid plaques was
examined using the Mann–Whitney test. Student’s t-
test was used for comparison of two groups of values
with normal distribution. Correlation was calculated
according to Pearson. The frequency rate was com-
pared using the test for two fractions. The Chi-squared
test with Yates modification was used for comparison
of differences in risk factors and coexisting diseases
distribution. The criterion for statistical significance
was p , 0:05:
Results
Patient demographics
Thirty-eight patients (26 men, 12 women, median age
67) were enrolled in the study. Twenty subjects had
symptomatic carotid stenosis and the other 18 patients
had no characteristic cerebral ischemic symptoms.
Most individuals were current and former smokers
ðn ¼ 33; 86:8%Þ: Among 33 smokers, 18 (47.4%) were
current smokers and 15 (39.5%) stopped smoking
more than one year ago. Among all the patients
enrolled in the study 25 (65.8%) had hypertension and
7 (18.4%) diabetes. Concomitant peripheral arterial
occlusive disease (PAOD) was found in 26 patients
(68.4%). Eighteen of these patients reported intermit-
tent claudication and eight individuals had no
symptoms of PAOD. Most of enrolled subjects were
overweight ðn ¼ 22Þ or obese ðn ¼ 11Þ: Mean carotid
stenosis was 75% (range, 50–95%) (Table 1).
There were no statistically significant differences
with respect to sex, age, risk factors distribution and
degree of stenosis between symptomatic and asymp-
tomatic patients. Symptomatic patients had a slightly
higher degree of internal carotid stenosis (Table 2).
All tested haemostatic factors were found in the
carotid plaque. The concentration of individual hae-
mostatic factors in the carotid plaques of patients with
symptomatic and asymptomatic carotid stenosis was
evaluated (Table 3). Statistically significant increased
concentration of TAT complexes in symptomatic
carotid plaques was found ðp , 0:04Þ (Fig. 1). There
was no difference in TAT concentration in the blood
plasma of symptomatic and asymptomatic patients.
No major differences between symptomatic and
asymptomatic patients were apparent with respect to
the concentration of t-PA, PAI-1 and D-dimers in the
carotid plaque (Table 3).
Fig. 1. The concentration of TAT in carotid atherosclerotic plaques and blood plasma of patients with symptomatic and
asymptomatic carotid stenosis. (ng/mg p; ng/ml).
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The influence of concomitant risk factors and
diseases on the haemostatic profile of the carotid
plaque was evaluated. Statistically significant
increased levels of TATcomplexes ðp , 0:01Þ; t-PA ðp ,
0:02Þ and D-dimers ðp , 0:02Þ in the carotid plaque of
diabetic patients have been demonstrated (Fig. 2).
There were no differences between plasma concen-
tration of tested HFs in diabetic and non-diabetic
patients. The concentration of D-dimers was also
elevated in the carotid plaques among claudicants
ðp , 0; 02Þ (Table 4).
The haemostatic composition of preocclusive car-
otid plaques ($90% of stenosis) did not differ from
those with less advanced stenosis (Table 4). There was
no difference in the concentration of tested haemo-
static factors in smokers and non-smokers and in
hypertensive and normotensive patients. The differ-
ences in the concentration of plasma lipids (LDL,
HDL, and TG) did not influence carotid plaque
haemostatic profile. The level of tested haemostatic
factors in the carotid plaque in different subgroups of
patients is presented in Table 4.
Antithrombin was present only in nine out of 38
carotid plaques (AT positive group). There were 17
patients with asymptomatic and 12 with symptomatic
carotid stenosis in the AT negative group. There was
only one patient with asymptomatic carotid stenosis in
the AT positive group. The test for two fractions
demonstrated that antithrombin can be found more
frequently in the carotid atherosclerotic plaques of
patients with symptomatic carotid stenosis ðp ,
0:006Þ:
The positive correlation between concentration of
antithrombin in the blood plasma and the carotid
plaque was found (AT positive group) (Table 5). There
was no correlation between concentration of other
tested haemostatic factors in carotid plaques and
blood plasma (Table 5).
Discussion
Many detailed studies on morphologic characteristics
of symptomatic carotid plaque (ruptures, ulcerations,
lumen thrombosis, and intraplaque hemorrhage) have
been performed.1 – 3 Histological analysis of sympto-
matic carotid plaque has been focused on fibrous cap
thickness, cap inflammation (macrophages, T cells)
and plaque core composition (cholesterol, extractable
lipids, collagen).2 Many of the studies mentioned
above have demonstrated there are histological differ-
ences in the characteristics of the carotid atherosclero-
tic plaque removed from symptomatic and
asymptomatic patients. Taking into consideration all
the reports it can be assumed that the symptomatic
carotid plaque is characterized by thin fibrous cap
containing large number of inflammatory cells (macro-
phages, T lymphocytes).2 Only one study has demon-
strated an increased expression of adhesion molecule
ICAM-1 in symptomatic carotid plaques.27 It was also
proven that morphology of the symptomatic carotid
plaque is different. The ultrasound examinations have
shown that symptomatic plaques are more frequently
echolucent with surface ruptures and ulcerations.2,3
Considering the crucial role of coagulation and
fibrinolysis in atherosclerotic plaque formation and
the connection of these processes with inflammatory
process it seems interesting to study haemostatic
profile of symptomatic and asymptomatic carotid
plaque. As yet, limited data have been published on
the thrombogenicity of the symptomatic carotid
Table 1. Patient demographics and risk factors.
Characteristic n (%)
Male 26 (68.4)
Symptomatic carotid stenosis 20 (52.6)
TIA 8 (21.1)
Stroke 13 (34.2)
Retinal embolism 3 (7.9)
Hypertension 25 (65.8)
CAD 17 (46.0)
Diabetes 7 (18.4)
PAOD 26 (68.4)
IC 18 (74.4)
Asymptomatic PAOD 8 (21.1)
Overweight (BMI 24.5–29) 22 (57.9)
Obesity (BMI .29) 11 (29.0)
Total cholesterol .200 mg/dl 19 (52.8)
Triglicerydes .200 mg/dl 6 (15.8)
Cholesterol LDL .100 mg/dl 26 (81.2)
Cholesterol HDL ,40 mg/dl 17 (50.0)
PAOD, peripheral arterial occlusive disease; CAD, coronary artery
disease; IC, intermittent claudication.
Table 2.
Sex, % male Age, (median) Stenosis, % (mean) HA, % DM, % CAD, % IC, %
Asymptomatic n ¼ 18 67 67 68 78 22 50 50
Symptomatic n ¼ 20 70 63 78 55 15 40 45
p ns* ns* ns† ns* ns* ns* ns*
HA, hypertension; DM, diabetes; CAD, coronary artery disease; IC, intermittent claudication.
*Chi-squared—Yates test.
†Test for two fractions.
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plaque.2 It has been demonstrated that treatment with
statins (e.g. atorvastatin) can reduce the inflammatory
and thrombotic phenotype of carotid plaque.28 The
influence of haemostatic factors (thrombin, t-PA, PAI-
1) on the formation of stable and unstable coronary
atherosclerotic plaque has been demonstrated.24,29,30
There are no reports available describing the concen-
tration of haemostatic factors in human carotid
plaques. Considering that hemodynamic environment
of coronary circulation is different from that of the
carotid arteries care should be taken in relating
findings from one vascular bed to another.
In our study the only statistically significant
difference in haemostatic factors concentration
between symptomatic and asymptomatic carotid
plaque was the level of thrombin–antithrombin
complexes (TAT). Higher concentration of TAT charac-
terized the symptomatic carotid plaque (Table 3, Fig.
1). The trend toward an increased concentration of
PAI-1 was also observed in symptomatic carotid
plaques but the difference did not reach the statistical
significance. It is possible that the number of patients
recruited to the study influences obtained results
(Table 3, Fig. 3).
Most of the plasma proteins can be found in the
vascular endothelium both of arterial healthy wall and
of those with atherosclerotic lesions. Usually the
plasma concentration of these proteins is dependent
on their concentration in the extracellular fluid.23 All
plasma haemostatic factors were present in the carotid
plaque in our study group. Antithrombin was
detected only in nine out of 38 carotid plaques (AT
positive group). Possibly, part of antithrombin was
fixed with thrombin forming TAT complexes. That
could be a reasonable explanation why antithrombin
was not detected in all carotid plaques. There was only
one patient with asymptomatic carotid stenosis in the
AT positive group. Majority of patients in this group
had cerebral ischemic symptoms ðn ¼ 8; 89%Þ: This
finding suggest that antithrombin or increased levels
of antithrombin (considering that part of AT molecules
were fixed with thrombin forming TATcomplexes) can
be found more frequently in the symptomatic carotid
plaque. Thrombin–antithrombin complexes (TAT)
were present in all carotid plaques. TAT concentration
was elevated in symptomatic carotid plaques. Antith-
rombin is a principal plasma inhibitor of thrombin.
The presence of this protein in the carotid plaque of
some (mainly symptomatic) patients with severe
carotid stenosis could indicate the plaque rupture
and intramural haemorrhage in these patients. We
have also observed a positive correlation between
concentration of antithrombin in the blood plasma and
the carotid plaque (AT positive group) what makes our
hypothesis more probable. The same significance
could have elevated concentration of thrombin–
antithrombin complexes in the symptomatic carotid
plaque. Preoperative duplex-scan examination with
Fig. 2. The concentration of TAT, t-PA and D-dimer in carotid plaques of non-diabetic and diabetic patients.
Table 3. The concentration of haemostatic factors in carotid atherosclerotic plaques of patients with symptomatic and asymptomatic
carotid stenosis. (mg p, milligram of protein).
Parameters All Symptomatic subjects Asymptomatic subjects p*
n X ^ SD n X ^ SD n X ^ SD
TAT (ng/mg p)† 38 15.96 ^ 14.55 20 20.35 ^ 15.02 18 11.08 ^ 12.69 p , 0:04
AT (%/mg p)‡ 9 0.41 ^ 0.35 8 0.43 ^ 0.37 1 0.23 ns
t-PA (ng/mg p)† 38 1.79 ^ 1.73 20 1.76 ^ 1.88 18 1.81 ^ 1.60 ns
PAI-1 (ng/mg p)† 38 14.90 ^ 9.61 20 16.71 ^ 10.64 18 12,90 ^ 8.16 ns
D-dimers (ng/mg p)† 38 744.37 ^ 479.20 20 740.81 ^ 426.03 18 748.32 ^ 544.88 ns
TAT, thrombin-antithrombin complexes; AT, antithrombin; t-PA, tissue plasminogen activator; PAI-1, plasminogen activator inhibitor type 1.
*Mann–Whitney test.
†ELISA.
‡Test based on chromogenic substrates.
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precise evaluation of plaque morphology could bring
important additional information and confirm the
hypothesis. We could not refer our results to pre-
operative duplex-scan examination because of varia-
bility of examinations qualifying to endarterectomy
performed in patients enrolled in the study (duplex-
scan made by different examiners; angiography).
Considering t-PA and PAI-1 as one of the most
controversial haemostatic factors playing a crucial role
in atherogenesis, we were particularly interested in
evaluation of t-PA and PAI-1 concentration in the
carotid atherosclerotic plaque. We wanted to demon-
strate whether there is any difference in the concen-
tration of t-PA and PAI-1 in carotid plaques of patients
with symptomatic and asymptomatic carotid stenosis.
We have not found statistically significant differences
in the t-PA and PAI-1 concentration in the sympto-
matic and asymptomatic carotid plaques (Table 4). As
we have mentioned above, although a statistically
significant relationship was lacking, PAI-1 concen-
tration showed a trend toward higher values in
symptomatic plaques (16.7 ng/mg vs. 12.9 ng/mg
protein) (Fig. 3). The lack of a significant correlation
may therefore result from the relatively small sample
size.
Multidirectional and potentially opposed activity of
t-PA and PAI-1 has been demonstrated in patients with
coronary arterial disease coexisting with diabetes.
Diabetic patients have an increased expression of
PAI-1 in coronary atherosclerotic plaques what should
protect them against destabilization but the incidence
of acute coronary syndrome in this group of patients is
extraordinarily high.18,22,23This paradox can be
explained by the increased expression of PAI-1 during
the process of atherogenesis which predispose to
formation of unstable, acellular plaques with high
lipid contents as a result of decreased VSMCs
migration.24
We have not found an increased concentration of
PAI-1 in carotid plaques of diabetic patients as it has
been demonstrated in coronary artery atherectomy
specimens.18 However, our diabetic patients had
elevated levels of t-PA in the carotid plaque.
In our study, the most distinct influence on the
carotid plaque haemostatic profile had diabetes
(higher values of TAT, t-PA and D-dimers) but we
have not observed higher frequency of cerebral
ischemic symptoms in diabetic patients. We can
assume that the difference in the haemostatic compo-
sition of carotid plaques in diabetic patients seems not
to affect symptomatology. Changes in the carotid
plaque haemostatic composition in diabetic patients
can be considered a local plaque characteristic because
we have not found statistically significant differences
Table 4. The concentration of haemostatic factors in carotid plaques in relation to degree of stenosis, risk factors and coexisting diseases.
TAT AT t-PA PAI-1 D-dimers
X ^ SD p* X ^ SD p* X ^ SD p* X ^ SD p* X ^ SD p*
$90% 15.7 ^ 12.9 ns 0.13 ^ 0.00 ns 0.75 ^ 0.84 ns 11.0 ^ 8.6 ns 554 ^ 328 ns
,90% 14.6 ^ 15.2 0.46 ^ 0.39 1.33 ^ 0.65 16.7 ^ 10.5 664 ^ 423
Chol $ 240 17.3 ^ 18.7 ns 0.31 ^ 0.17 ns 1.60 ^ 1.70 ns 12.0 ^ 11.3 ns 780 ^ 446 ns
Chol , 240 16.4 ^ 14.0 0.44 ^ 0.40 1.87 ^ 1.81 15.7 ^ 9.5 747 ^ 509
LDL $ 130 12.1 ^ 11.1 ns 0.55 ^ 0.44 ns 1.83 ^ 1.56 ns 16.6 ^ 11.9 ns 623 ^ 359 ns
LDL , 130 15.8 ^ 12.3 0.19 ^ 0.09 1.90 ^ 2.12 12.7 ^ 7.5 864 ^ 564
BMI $ 29 16.9 ^ 12.1 ns 0.38 ^ 0.20 ns 1.95 ^ 1.55 ns 17.9 ^ 10.5 ns 837 ^ 494 ns
BMI , 29 14.2 ^ 15.3 0.44 ^ 0.47 1.70 ^ 1.92 13.5 ^ 9.3 650 ^ 460
Nikot.(þ ) 16.3 ^ 14.9 ns 0.46 ^ 0.43 ns 1.72 ^ 1.77 ns 15.0 ^ 9.8 ns 727 ^ 479 ns
Nikot.(2) 13.7 ^ 13.6 0.31 ^ 0.11 2.25 ^ 1.58 13.9 ^ 9.2 862 ^ 520
HA(þ ) 15.0 ^ 14.6 ns 0.34 ^ 0.19 ns 1.67 ^ 1.69 ns 15.0 ^ 9.7 ns 783 ^ 515 ns
HA(2) 17.9 ^ 14.9 0.49 ^ 0.52 2.02 ^ 1.87 14.8 ^ 9.9 670 ^ 410
IC(þ) 15.8 ^ 11.9 ns 0.67 ^ 0.57 ns 1.81 ^ 2.16 ns 12.7 ^ 7.4 ns 907 ^ 467
lt;0.02
IC(2) 16.1 ^ 16.9 0.28 ^ 0.09 1.77 ^ 1.28 16.8 ^ 11.1 598 ^ 451
DM(þ) 28.7 ^ 12.1 ,0.01 0.76 ^ 0.71 ns 3.22 ^ 2.67 ,0.02 11.5 ^ 3.9 ns 1169 ^ 437 ,0,02
DM(2) 13.1 ^ 13.6 0.31 ^ 0.17 1.46 ^ 1.30 15.7 ^ 10.4 648 ^ 440
HA, hypertension; IC, intermittent claudication; DM, diabetes; Chol $ 240, total plasma cholesterol level $240 mg/dl; BMI, body mass
index; Nikot.(þ ), smokers; Nikot.(2), non-smokers; $90%, ICA stenosis $90%; ,90%, ICA stenosis ,90%; TAT, t-PA, PAI-1, D-dimers
(ng/mg p); AT (%/mg p).
*Mann–Whitney test.
Table 5. The correlation between concentrations of haemostatic
factors in carotid plaques and in blood plasma (R, correlation
coefficient of Pearson).
Parameters n Rxy p-value
TAT 34 0.168 0.35
AT 9 0.761 0.02
t-PA 30 20.059 0.74
PAI-1 35 20.099 0.61
D-dimers 34 0.153 0.15
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between plasma concentration of tested HFs in
diabetic and non-diabetic subjects. We have found
elevated concentration of D-dimers in carotid plaques
of claudicants. We consider this finding as the sign of
advanced general arteriosclerosis. The positive associ-
ation between plasma D-dimers concentration and
risk of coronary artery disease has already been
reported.31 – 35
As the main finding we consider a significant
association of higher TAT concentration in the carotid
plaque with the occurrence of cerebral ischemic
symptoms. Thus, in line with findings in coronary
artery disease our data suggest an important role of
haemostatic factors in determining carotid plaque
susceptibility for destabilization process. It was sur-
prising to find diabetes as the main risk factor
changing the concentration of haemostatic factors in
the carotid plaque.
Conclusions
All the evaluated haemostatic factors are components
of carotid atherosclerotic plaque.
Symptomatic carotid plaque contains an increased
concentration of thrombin-antithrombin
complexes.
Diabetes is the most distinct factor, which exerts its
influence on carotid plaque haemostatic profile.
There is a positive correlation between concentration
of antithrombin in the blood plasma and the carotid
plaque homogenates when antithrombin is
detected in carotid plaque.
There is no correlation between concentration of TAT,
t-PA, PAI-1 and D-dimers in the carotid plaque
homogenates and blood plasma.
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